Alpha-synuclein and presynaptic function: Implications for Parkinson's disease

NeuroMolecular Medicine

Volumn 2, Issue 2, 2002, Pages 115-129

  Lykkebo, Simon ^a   Jensen, Poul Henning ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Axon; Lewy body; Parkinson's disease; Synapse; Synuclein; Vesicles

Indexed keywords

ALPHA SYNUCLEIN; CARRIER PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

DEGENERATIVE DISEASE; GENE EXPRESSION; HUMAN; LEWY BODY; NERVE FIBER; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW; SYNAPSE VESICLE; ANIMAL; BRAIN; CELL COMPARTMENTALIZATION; CELL MEMBRANE; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTOSOME;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CELL COMPARTMENTATION; CELL MEMBRANE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; SYNUCLEINS;

EID: 0042477558     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/NMM:2:2:115     Document Type: Review

References (102)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W. H., Castillo P. E., et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Ackmann M., Wiech H., and Mandelkow E. (2000) Nonsaturable binding indicates clustering of tau on the microtubule surface in a paired helical filament-like conformation. J. Biol. Chem. 275, 30,335-30,343.
3. Adams J. D. Jr. and Odunze I. N. (1991) Oxygen free radicals and Parkinson's disease. Free Radic. Biol. Med. 10, 161-169.
4. Alim M. A., Hossain M. S., Arima K., Takeda K., Izumiyama Y., Nakamura M., etal. (2002) Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 277, 2112-2117.
5. Ancolio K., Alves da Costa C., Ueda K., and Checler F. (2000) Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285, 79-82.
6. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
7. Bayer T.A., Jakala P., Hartmann T., Egensperger R., Buslei R., Falkai P., et al. (1999) Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport 10, 2799-2803.
8. Bennett M. C., Bishop J. F., Leng Y., Chock P. B., Chase T. N., and Mouradian M. M. (1999) Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274, 33,855-33,858.
9. Campbell D. S. and Holt C. E. (2001) Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 32, 1013-1026.
10. Campion D., Martin C., Heilig R., Charbonnier F., Moreau V., Flaman J. M., et al. (1995) The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 26, 254-257.
11. Choi P., Golts N., Snyder H., Chong M., Petrucelli L., Hardy J., et al. (2001) Co-association of parkin and alpha-synuclein. Neuroreport 12, 2839-2843.
12. Cole R. N. and Hart G. W. (2001) Cytosolic O-glycosylation is abundant in nerve terminals. J. Neurochem. 79, 1080-1089.
13. Cole N. B., Murphy D. D., Grider T., Rueter S., Brasaemle D., and Nussbaum R. L. (2002) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem. 277, 6344-6352.
14. Conway K. A., Harper J. D., and Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
15. Conway K. A., Harper J. D., and Lansbury P. T. Jr. (2000a) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563.
16. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E., and Lansbury P. T. Jr. (2000b) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576.
17. Crowther R. A., Jakes R., Spillantini M. G., and Goedert M. (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436, 309-312.
18. Davidson W. S., Jonas A., Clayton D. F., and George J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
19. Dickson D. W., Liu W., Hardy J., Farrer M., Mehta N., Uitti R., et al. (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 155, 1241-1251.
20. Dickson D. W. (2001) Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol. 14, 423-432.
21. Dillman J. F. 3rd, Dabney L. P., and Pfister K. K. (1996) Cytoplasmic dynein is associated with slow axonal transport. Proc. Natl. Acad. Sci. USA 93, 141-144.
22. Eliezer D., Kutluay E., Bussell R. Jr., and Browne G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073.
23. Engelender S., Kaminsky Z., Guo X., Sharp A. H., Amaravi R. K., Kleiderlein J. J., et al. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22, 110-114.
24. Feany M. B. and Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
25. Forno L. (1987) The Lewy body in Parkinson's disease. Adv. Neurol. 45, 35-43.
26. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., et al. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol. 4, 160-164.
27. Gai W. P., Power J. H., Blumbergs P. C., and Blessing W. W. (1998) Multiple-system atrophy: a new alpha-synuclein disease? Lancet 352, 547-548.
28. Gai W. P., Power J. H., Blumbergs P. C., Culvenor J. G., and Jensen P. H. (1999) Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J. Neurochem. 73, 2093-2100.
29. Galvin J. E., Uryu K., Lee V. M., and Trojanowski J. Q. (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. USA 96, 13,450-13,455.
30. Galvin J. E., Lee V. M., and Trojanowski J. Q. (2001a) Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58, 186-190.
31. Galvin J. E., Schuck T. M., Lee V. M., and Trojanowski J. Q. (2001b) Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. Exp. Neurol. 168, 347-355.
32. George J. M., Jin H., Woods W. S., and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-723.
33. Goldberg M. S. and Lansbury P. T. Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell. Biol. 2, 115-119.
34. Gomez-Tortosa E., Newell K., Irizarry M. C., Sanders J. L., and Hyman B. T. (2000) alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. (Berl) 99, 352-357.
35. Giasson B. I., Uryu K., Trojanowski J. Q., and Lee V. M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622.
36. Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
37. Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501.
38. Hashimoto M., Hsu L. J., Sisk A., Xia Y., Takeda A., Sundsmo M., et al. (1998) Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799, 301-306.
39. Hashimoto M., Hsu L. J., Xia Y., Takeda A., Sisk A., Sundsmo M., et al. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10, 717-721.
40. Hirokawa N. (1994) The neuronal cytoskeleton: roles in neuronal morphogenesis and organelle transport. Prog. Clin. Biol. Res. 390, 117-143.
41. Hirokawa N. (1998) Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279, 519-526.
42. Hsu L. J., Mallory M., Xia Y., Veinbergs I., Hashimoto M., Yoshimoto M., et al. (1998) Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J. Neurochem. 71, 338-344.
43. Irizarry M. C., Kim T. W., McNamara M., Tanzi R. E., George J. M., Clayton D. F., et al. (1996) Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889-895.
44. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A., et al. (1995) The precursor protein of non-Abeta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
45. Jakes R., Spillantini M. G., and Goedert M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32.
46. Jenco J. M., Rawlingson A., Daniels B., and Morris A. J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37, 4901-4909.
47. Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G., and Goedert M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26,292-26,294.
48. Jensen P. H., Hager H., Nielsen M. S., Hojrup P., Gliemann J., and Jakes R. (1999a) alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274, 25,481-25,489.
49. Jensen P. H., Li J. Y., Dahlstrom A., and Dotti C. G. (1999b) Axonal transport of synucleins is mediated by all rate components. Eur. J. Neurosci. 11, 3369-3376.
50. Jensen P. H., Islam K., Kenney J., Nielsen M. S., Power J., and Gai W. P. (2000) Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments. J. Biol. Chem. 275, 21,500-21,507.
51. Jensen P. H. and Gai W. P. (2001) Alpha-synuclein. Axonal transport, ligand interaction and neurodegeneration. Adv. Exp. Med. Biol. 487, 129-134.
52. Jo E., McLaurin J., Yip C. M., St George-Hyslop P., and Fraser P. E. (2000) alpha-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34,328-34,334.
53. Julien J. P. (2001) Amyotrophic lateral sclerosis unfolding the toxicity of the misfolded. Cell 104, 581-591.
54. Kahle P. J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373.
55. Kahle P. J., Neumann M., Ozmen L., Muller V., Odoy S., Okamoto N., et al. (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159, 2215-2225.
56. Kamal A., Stokin G. B., Yang Z., Xia C. H., and Goldstein L. S. (2000) Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28, 449-459.
57. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2795.
58. Krüger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
59. Lang A. E. and Lozano A. M. (1998) Parkinson's disease. N. Engl. J. Med. 339, 1030-1053.
60. Lavedan C., Leroy E., Dehejia A., Buchholtz S., Dutra A., Nussbaum R. L., et al. (1998) Identification, localization and characterization of the human gamma-synuclein gene. Hum. Genet. 103, 106-112.
61. Lee F. J., Liu F., Pristupa Z. B., and Niznik H. B. (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926.
62. Lee H. J., Choi C., and Lee S. J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671-678.
63. Lewy F. H. (1912) Paralysis agitans, I Pathologische Anatomie, Handbuch der Neurologie, Band III, Springer Verlag, Germany, pp. 920-933.
64. Maroteaux L., Campanelli J. T., and Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815.
65. Maroteaux L. and Scheller R. H. (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11, 335-343.
66. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
67. McKeith I. G., Perry E. K., and Perry R. H. (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 53, 902-905.
68. McLean P. J., Kawamata H., Ribich S., and Hyman B. T. (2000) Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275, 8812-8816.
69. Murphy D. D., Rueter S. M., Trojanowski J. Q., and Lee V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220.
70. Nakajo S., Tsukada K., Kameyama H., Furuyama Y., and Nakaya K. (1996) Distribution of phosphoneuroprotein 14 (PNP 14) in vertebrates: its levels as determined by enzyme immunoassay. Brain Res. 741, 180-184.
71. Narayanan V. and Scarlata S. (2001) Membrane binding and self-association of alpha-synucleins. Biochemistry 40, 9927-9934.
72. Nielsen M. S., Vorum H., Lindersson E., and Jensen P. H. (2001) Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 276, 22,680-22,684.
73. Nirenberg M. J., Vaughan R. A., Uhl G. R., Kuhar M. J., and Pickel V. M. (1996a) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16, 436-447.
74. Nirenberg M. J., Chan J., Liu Y., Edwards R. H., and Pickel V. M. (1996b) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J. Neurosci. 16, 4135-4145.
75. Ochs S. (1975) Retention and redistribution of proteins in mammalian nerve fibres by axoplasmic transport. J. Physiol. 253, 459-475.
76. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., et al. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390-397.
77. Paik S. R., Shin H. J., and Lee J. H. (2000) Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys. 378, 269-277.
78. Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M., et al. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053-8061.
79. Payton J. E., Perrin R. J., Clayton D. F., and George J. M. (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res. Mol. Brain Res. 95, 138-145.
80. Perrin R. J., Woods W. S., Clayton D. F., and George J. M. (2000) Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34,393-34,398.
81. Petersen K., Olesen O. F., and Mikkelsen J. D. (1999) Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91, 651-659.
82. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
83. Pronin A. N., Morris A. J., Surguchov A., and Benovic J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26,515-26,522.
84. Rochet J. C., Conway K. A., and Lansbury P. T. Jr. (2000a) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39, 10,619-10,626.
85. Rochet J. C. and Lansbury P. T. Jr. (2000b) Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10, 60-68.
86. Shah J. V. and Cleveland D. W. (2002) Slow axonal transport: fast motors in the slow lane. Curr. Opin. Cell. Biol. 14, 58-62.
87. Sharon R., Goldberg M. S., Bar-Josef I., Betensky R. A., Shen J., and Selkoe D. J. (2001) alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. USA 98, 9110-9115.
88. Shea T. B. and Flanagan L. A. (2001) Kinesin, dynein and neurofilament transport. Trends Neurosci. 24, 644-648.
89. Shibayama-Imazu T., Okahashi I., Omata K., Nakajo S., Ochiai H., Nakai Y., et al. (1993) Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). Brain Res. 622, 17-25.
90. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., et al. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269.
91. Souza J. M., Giasson B. I., Chen Q., Lee V. M., and Ischiropoulos H. (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18,344-18,349.
92. Spillantini M. G., Divane A., and Goedert M. (1995) Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics 27, 379-381.
93. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
94. Tofaris G. K., Layfield R., and Spillantini M. G. (2001) alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22-26.
95. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11,282-11,286.
96. Ueda K., Saitoh T., and Mori H. (1994) Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. Biochem. Biophys. Res. Commun. 205, 1366-1372.
97. Van der Putten H., Wiederhold K. H., Probst A., Barbieri S., Mistl C., Danner S., et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021-6029.
98. Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C., et al. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
99. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M., et al. (1998) Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. (Berl) 96, 445-452.
100. Weinreb P. H., Zhen W., Poon A. W., Conway K. A., and Lansbury P. T. Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13,709-13,715.
101. Withers G. S., George J. M., Banker G. A., and Clayton D. F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99, 87-94.
102. Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M., and Biere A. L. (1999) alpha-synuclein fibrillogenesis is nucleation-dependent process. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19,509-19,512.